Literature DB >> 22493216

Azacitidine after allo-SCT: the good without the bad?

Mohamad Mohty1, Patrice Chevallier.   

Abstract

Entities:  

Year:  2012        PMID： 22493216     DOI： 10.1182/blood-2012-02-406678

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Baron; M Labopin; D Blaise; L Lopez-Corral; S Vigouroux; C Craddock; M Attal; P Jindra; H Goker; G Socié; P Chevallier; P Browne; A Sandstedt; R F Duarte; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

2.  Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Myriam Labopin; Marie Robin; Juergen Finke; Patrice Chevallier; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Henrik Sengelov; Didier Blaise; Thomas Luft; Michael Hallek; Nicolaus Kröger; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

3.  Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  P Chevallier; M Labopin; N Milpied; K Bilger; G Socié; I Yakoub-Agha; M Michallet; C-E Bulabois; S Maury; Y Beguin; J-O Bay; D Blaise; N Maillard; G Guillerm; E Daguindeau; N Raus; M Mohty
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483

Review 4.  Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.

Authors:  Salvatore Leotta; Annalisa Condorelli; Roberta Sciortino; Giulio Antonio Milone; Claudia Bellofiore; Bruno Garibaldi; Giovanni Schininà; Andrea Spadaro; Alessandra Cupri; Giuseppe Milone
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241

5.  Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors:  Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-09       Impact factor: 5.742

6.  [Advances in hematopoietic stem cell transplantation for hematological disease].

Authors:  Y Wang; X J Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14

7.  Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS-ERG and early relapse after allogeneic blood stem cell transplantation: A case report.

Authors:  Dai Keino; Takashi Mori; Mizuho Morimoto; Kensuke Kondo; Tetsuya Mori; Akitoshi Kinoshita
Journal:  Clin Case Rep       Date:  2019-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.